Enovis (NYSE: ENOV) Beats Q1 2026 Estimates, Reaffirms Full-Year Guidance
Enovis posted $589M in Q1 sales and $0.89 adjusted EPS, topping estimates. Reconstructive segment led growth as the company reiterated its full-year outlook.
Enovis Corporation (NYSE: ENOV) is a company in the Health Care sector, listed on the NYSE. This page collects all Alpha Stocks Insight coverage of ENOV: earnings reports, analyst actions, and company news, updated as new articles are published. 2 articles since May 7, 2026.
ENOV jumps nearly 10% on Q1 earnings beat and reaffirmed guidance, bouncing back from prior weakness.
Enovis posted $589M in Q1 sales and $0.89 adjusted EPS, topping estimates. Reconstructive segment led growth as the company reiterated its full-year outlook.
Important Legal Disclaimer
This is for informational purposes only and is not financial, investment, or tax advice. Past performance is no guarantee of future results. We are not licensed advisors. For Swiss residents: This does not constitute a public offer under FINSA. For EU residents: Not MiFID II compliant advice. For US residents: Not SEC-registered advice. Always consult a qualified professional. Investing involves risk of loss.
Affiliate disclosure: This site may contain affiliate links to brokerage platforms. If you open an account through one of our links, we may earn a commission at no additional cost to you. Affiliate relationships do not influence our editorial content or stock coverage decisions.
Important Legal Disclaimer: This is for informational purposes only and is not financial, investment, or tax advice. Past performance is no guarantee of future results. We are not licensed advisors. For Swiss residents: This does not constitute a public offer under FINSA. For EU residents: Not MiFID II compliant advice. For US residents: Not SEC-registered advice. Always consult a qualified professional. Investing involves risk of loss.